JP Morgan Chase’s Minerva Neurosciences NERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-17
| Closed | -$29 | – | 7457 |
|
|
2025
Q1 | $29 | Hold |
17
| – | – | ﹤0.01% | 7076 |
|
|
2024
Q4 | $38 | Buy |
+17
| New | +$40 | ﹤0.01% | 7179 |
|
|
2023
Q4 | – | Sell |
-9
| Closed | -$62 | – | 7751 |
|
|
2023
Q3 | $62 | Sell |
9
-4,508
| -100% | -$40.4K | ﹤0.01% | 6967 |
|
|
2023
Q2 | $41.3K | Buy |
4,517
+4,514
| +150,467% | +$23.8K | ﹤0.01% | 5762 |
|
|
2023
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7054 |
|
|
2022
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 6840 |
|
|
2022
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 6719 |
|
|
2022
Q2 | $0 | Sell |
3
-78
| -96% | -$319 | ﹤0.01% | 6735 |
|
|
2022
Q1 | $1K | Buy |
+81
| New | +$497 | ﹤0.01% | 6486 |
|
|
2021
Q4 | – | Sell |
-2,162
| Closed | -$30K | – | 6848 |
|
|
2021
Q3 | $30K | Sell |
2,162
-12,658
| -85% | -$190K | ﹤0.01% | 5964 |
|
|
2021
Q2 | $275K | Sell |
14,820
-8,326
| -36% | -$179K | ﹤0.01% | 5070 |
|
|
2021
Q1 | $541K | Buy |
23,146
+288
| +1% | +$7.2K | ﹤0.01% | 4630 |
|
|
2020
Q4 | $428K | Buy |
22,858
+7,984
| +54% | +$201K | ﹤0.01% | 4465 |
|
|
2020
Q3 | $382K | Sell |
14,874
-1,410
| -9% | -$38.1K | ﹤0.01% | 4100 |
|
|
2020
Q2 | $471K | Buy |
16,284
+3,356
| +26% | +$197K | ﹤0.01% | 3882 |
|
|
2020
Q1 | $622K | Sell |
12,928
-36,700
| -74% | -$2.21M | ﹤0.01% | 3713 |
|
|
2019
Q4 | $2.82M | Buy |
49,628
+10,465
| +27% | +$461K | ﹤0.01% | 3118 |
|
|
2019
Q3 | $2.43M | Buy |
39,163
+809
| +2% | +$45.8K | ﹤0.01% | 3285 |
|
|
2019
Q2 | $1.68M | Sell |
38,354
-5,367
| -12% | -$269K | ﹤0.01% | 3498 |
|
|
2019
Q1 | $2.75M | Buy |
43,721
+6,521
| +18% | +$392K | ﹤0.01% | 3110 |
|
|
2018
Q4 | $2.01M | Sell |
37,200
-8,012
| -18% | -$586K | ﹤0.01% | 3273 |
|
|
2018
Q3 | $4.54M | Sell |
45,212
-4,039
| -8% | -$304K | ﹤0.01% | 2816 |
|
|
2018
Q2 | $3.25M | Sell |
49,251
-25,692
| -34% | -$1.56M | ﹤0.01% | 3025 |
|
|
2018
Q1 | $3.75M | Sell |
74,943
-7,236
| -9% | -$348K | ﹤0.01% | 2811 |
|
|
2017
Q4 | $3.98M | Buy |
82,179
+33,641
| +69% | +$1.67M | ﹤0.01% | 2862 |
|
|
2017
Q3 | $2.83M | Buy |
+48,538
| New | +$2.78M | ﹤0.01% | 2947 |
|
|
2017
Q2 | – | Sell |
-4,357
| Closed | -$282K | – | 5121 |
|
|
2017
Q1 | $282K | Sell |
4,357
-1,890
| -30% | -$147K | ﹤0.01% | 3945 |
|
|
2016
Q4 | $587K | Buy |
+6,247
| New | +$638K | ﹤0.01% | 3682 |
|
Other funds holding NERV
AC
ACM
JP Morgan Chase's NERV Position: Q2 2025 in Review
JP Morgan Chase sold out of Minerva Neurosciences (NERV) in Q2 2025, closing a stake of 17 shares — an estimated $29 sold.
JP Morgan Chase first reported a position in NERV in Q4 2016 and held it in 28 quarters. The position peaked at $4.54M in Q3 2018. 21 funds tracked by Wall St. Rank hold NERV as of Q2 2025.
- JP Morgan Chase reported no remaining Minerva Neurosciences position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 17 Minerva Neurosciences shares in Q2 2025, an estimated $29.
- JP Morgan Chase first reported a position in Minerva Neurosciences in Q4 2016 and held it in 28 quarters.
- JP Morgan Chase's Minerva Neurosciences position peaked at $4.54M in Q3 2018.
- 21 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.